Celares GmbH
General information
Celares GmbH
Robert-Roessle-Str. 10
Gebäude D80
13125 Berlin, Berlin
Germany
Contact person: Ralf Krähmer, Chief Scientific Officer and Business Development
Company main phone: +49 (30) 94892350
Company main fax: +49 (30) 94892351
Website: https://www.celares.com
Robert-Roessle-Str. 10
Gebäude D80
13125 Berlin, Berlin
Germany
Contact person: Ralf Krähmer, Chief Scientific Officer and Business Development
Company main phone: +49 (30) 94892350
Company main fax: +49 (30) 94892351
Website: https://www.celares.com
| Year founded: | 2003 |
| Source of foundation: | Independent foundation |
Corporate description / mission:
Celares GmbH is an established conjugation and drug delivery company, which provides customized solutions. The company develops and produces new, biocompatible drug delivery systems that are based on polyethylene glycol and other amphiphilic polymers. Moreover, celares is a technology provider for multiplexing of large and small molecules with own IP. The technologies are ready for out-licensing.
Celares GmbH is an established conjugation and drug delivery company, which provides customized solutions. The company develops and produces new, biocompatible drug delivery systems that are based on polyethylene glycol and other amphiphilic polymers. Moreover, celares is a technology provider for multiplexing of large and small molecules with own IP. The technologies are ready for out-licensing.
State of ownership: Subsidiary
Headquarters: HQ: No
Headquarters: HQ: No
Remarks on ownership / listings
Part of Biosynth Group Limited.
Part of Biosynth Group Limited.
Categorization
| Sector: |
|
| Subsector: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Description of products:
- Process development for production of conjugated drugs
- Development and validation of analytical
methods
- Supply of conjugated drugs for in-vitro and
animal studies
- Synthesis of tailor-made PEG, Linker and polymers
- Synthesis of Linker-Drug conjugates for ADC development
- GMP production of activated PEG
- Process development for production of conjugated drugs
- Development and validation of analytical
methods
- Supply of conjugated drugs for in-vitro and
animal studies
- Synthesis of tailor-made PEG, Linker and polymers
- Synthesis of Linker-Drug conjugates for ADC development
- GMP production of activated PEG
Special IP situation:
IP in multiplexing technologies:
a) PaSmax® particular for multiplexing small-molecules, such as drugs to attach them to antibodies
b) celaSTAR particular for multiplexing large molecules to make use of a strong multivalence effect
IP in multiplexing technologies:
a) PaSmax® particular for multiplexing small-molecules, such as drugs to attach them to antibodies
b) celaSTAR particular for multiplexing large molecules to make use of a strong multivalence effect
Collaborations & Clients
Partnering strategy / collaborations:
modular collaboration agreements, e.g. feasibility study, product and process development, contract manufacturing, anayltical services.
modular collaboration agreements, e.g. feasibility study, product and process development, contract manufacturing, anayltical services.
Client portfolio (as relevant):
small and large biotech and pharma; drug delivery specialists; diagnostic companies
small and large biotech and pharma; drug delivery specialists; diagnostic companies
© 2024 Biotechgate by Venture Valuation